1. © Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor

2. PharmaVitae: Baxter International Inc. HC00068-037 Slidepack 12/11 quality dataexpert analysisintuitive delivery the home of Business Intelligence

3. Baxter prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16

4. Baxter financial performance ($m), 2004–16

5. 28.6 27.2 26.6 9.5 8.1 7.7 10.9 26.6 23.2 29.9 Blood coagulation factors market share, %, 2010 & 2016 (ranked by 2010 market share) 0% 20% 40% 60% 80% 100% 20102016 Year Proportion of market (%) Novo NordiskBaxterBayerCSLPfizerBiogen Idec

6. Baxter prescription sales performance ($m), scenario analysis, 2004-16 2010-16 CAGR = 3.8% 2010-16 CAGR = 2.5% CAGR = compound annual growth rate

7. SWOT analysis of Baxter Robust financial position, through controlled operating cost expenditure Broad molecule type coverage, spanning therapeutic proteins, monoclonal antibodies, small molecules and vaccines Strengths Business heavily reliant on regular human blood/plasma donations Weaknesses Addressing an area of high unmet need with Gammagard for Alzheimer’s disease – currently in Phase III trials Subcutaneous Gammagard to improve patient compliance and boost sales growth of the company’s ‘antibody therapy’ franchise Further ‘bolt-on’ acquisitions to expand technological capabilities Opportunities Failure to progress Gammagard for AD onto the market Declining hemophilia A market share through the launch of long lasting pipeline hemophilia A therapies Intensifying competition in the immunoglobulin (Ig) replacement therapy area. Threats

8. Baxter timeline

9. Current corporate structure Medication Delivery RenalBioscience ‘Medical Products’ (2011)

10. Current corporate structure

11. Baxter prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16

12. Key product sales ($m), 2004–16

13. Baxter key product growth drivers and resistors ($m), 2004–10

14. Baxter key product growth drivers and resistors ($m), 2010–16

15. Baxter prescription pharmaceutical sales by therapy area ($m), 2004–16

16. Baxter prescription pharmaceutical sales by geographic region ($m), 2004–16

17. Baxter launch, core and expiry configuration, sales ($m), 2010–16

18. Baxter prescription pharmaceutical sales by molecule type ($m), 2004–16

19. Baxter prescription pharmaceutical sales by source of product ($m), 2004–16

20. Baxter operating revenue/cost analysis ($m), 2004–16

21. © Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor